Redeye reviews BioInvent’s second key opinion leader (KOL) event of 2026, highlighting clinical development updates for its two lead blood c...
BioInvent hosted a virtual KOL event yesterday focusing on BI-1808 in advanced ovarian cancer.
The most recent readout with BI-1808 in combination with pembrolizumab in ovarian cancer, released yesterday evening, further strengthens ou...
Today, new data from BI-1808 in cutaneous T-cell lymphoma were presented.
Redeye comments on BioInvent's Q1 report 2026, which was a transitional quarter with limited news since our Q4 review.
Redeye reviews BioInvent's Q4 report 2025. Following a string of positive readouts from BI-1206 and BI-1808 in November - January, in partic...
Redeye’s conviction in BI-1808 increases with the latest readout in platinum-resistant ovarian cancer.
After publishing strong data with BI-1808 yesterday, BioInvent returns with a positive readout with the BI-1206 triplet in NHL.
Redeye is increasingly optimistic about BI-1808. In the latest readout presented at ASH, 6 out of 13 patients with CTCL presented a response...
BioInvent will present new data from BI-1206 (triplet) and BI-1808 (T-cell lymphoma) at ash.
Redeye reviews BioInvent's Q3 report 2025. The company is doubling down on BI-1206 and BI-1808.
Redeye comments on the updated clinical data from the phase I study combining the oncolytic virus TB-001 with pembrolizumab that will be pre...
Redeye comments on BioInvent’s Q2 report 2025. New positive results with BI-1206 in solid tumours and Non-Hodgkin lymphoma and with BI-1808 ...
Redeye provides a comment on this week’s news flow, with new data on BI-1206 in solid tumours and BI-1808 in T-cell lymphoma.
Redeye endorses BioInvent's divestment of its royalty and milestone rights to mezagitamab.
Redeye is bullish about the new results with BI-1808 in cutaneous T-cell lymphoma.
Redeye comments on BioInvent’s first quarter in 2025.
Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInvent.
Redeye comments on BioInvent's fourth-quarter report 2024.
Redeye comments on the new data from the triple combination study of BI-1206 and the phase I monotherapy data for BI-1910.
Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of BI-1206 in combination with rituximab in...
Redeye comments on BioInvent's new positive data with BI-1808 and BT-001.
Redeye comments on BioInvent's Q2 report 2024. Positive new results from BI-1206 in lymphoma and solid tumours and from BI-1808 were present...
BioInvent will present new positive data for BI-1206 in solid tumours and BI-1808 at ASCO.
Redeye is optimistic about the new data from lymphoma patients treated with subcutaneous as well as intravenous BI-1206.
Redeye comments on BioInvent's Q1 report 2024.
Redeye is optimistic about the new agreement with MSD/Merck to provide Keytruda for the combination part of the phase I/IIa study of BI-1910...
Redeye finds the interim results announced by CASI today reinforce those already published by BioInvent.
Redeye reviews BioInvent’s fourth quarter. The company now has six active clinical programs with several readouts this year, which may be tr...
Redeye views the collaboration with AstraZeneca in lymphoma as another quality stamp for BI-1206.
We comment on the termination in this note. Due to the early stage of the program, it does not influence our base case.
Redeye comments on the first phase I clinical data on BI-1607 communicated yesterday by BioInvent.
Redeye comments on BioInvent’s TNFR2 project BI-1808 after strong phase I results presented at SITC this weekend.
Redeye comments on the third quarter report of BioInvent.
Today, BioInvent announced the initiation of the phase IIa monotherapy part of the study of BI-1808, which we discuss in this note.
Since our last update, new readouts have been published with BI-1808 and BI-1206 in solid tumours.
Redeye comments on the positive readout from the phase I/IIa trial with the anti-TNFR2 antibody BI-1808 in advanced cancer.
Redeye comments on the new readout from the clinical study of BI-1206 in solid tumours, which presents additional positive clinical data.
Redeye comments on the positive results with BT-001 in the phase I study of solid tumours and updates its Base Case.
Redeye comments on BioInvent's first quarter report of 2023.
Redeye comments on the new data presented by BioInvent from the intravenous arm of the study.
Redeye comments on BioInvent's Q4 report. The most significant development in the period is the initiation of a phase I study with a new sub...
BioInvent had an R&D day on December 8, 2022, which provided an overview of the company’s scientific projects as of this date.
Redeye comments on BioInvents report for the third quarter, which saw a further strengthening of the financial position and progress in the ...
Redeye comments on BioInvent’s completed dose escalation (part A) in the phase I/IIa trial of BI-1808 in advanced cancer.
Redeye comments on BioInvent's second quarter report.
Redeye makes an adjustment to the project’s LOA based on results from BT-001’s phase I trial, part A.
Redeye views the deal with Exelixis, which provides BioInvent with a USD 25m upfront fee, as a useful cash injection and another validation ...
Redeye is encouraged by the positive End-of-Phase I meeting with the FDA and provides a brief comment.
Redeye provides a comment on BioInvent's first quarter report.
Redeye comments on BioInvent's Q4 report.
Redeye sticks to its positive view following the Q2 report and recent project news flow.
